miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells

Journal of Bioscience and Bioengineering

Volumn 120, Issue 4, 2015, Pages 351-358

  Lee, Seul Ah ^a   Kim, Jae Sung ^a   Park, Sun Young ^a   Kim, Heung Joong ^a   Yu, Sun Kyoung ^a   Kim, Chun Sung ^a   Chun, Hong Sung ^a   Kim, Jeongsun ^b   Park, Jong Tae ^c   Go, Daesan ^a   Kim, Do Kyung ^a  

^a Chosun University   (South Korea)

^b Gwangju Health University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Apoptosis; MiR 203; Oral cancer cells; Tumor suppressor; Yes 1

Indexed keywords

CELL DEATH; CYTOLOGY; DISEASES; GENE EXPRESSION; GENES; RNA; TUMORS;

ANTI-CANCER THERAPEUTICS; DOSE-DEPENDENT MANNER; LUCIFERASE ACTIVITY ASSAYS; MIR-203; ORAL CANCER CELLS; TUMOR SUPPRESSORS; UNTRANSLATED REGIONS; YES-1;

CELLS;

LUCIFERASE; MICRORNA; MICRORNA 203; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRN203 MICRORNA, HUMAN; PROTEIN KINASE YES; YES1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KB CELL LINE; KERATINOCYTE; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; ORAL CANCER CELL LINE; TUMOR SUPPRESSOR GENE; YES 1 GENE; BIOSYNTHESIS; DNA MICROARRAY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUTH TUMOR; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; MOUTH NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-YES; RNA, MESSENGER; TRANSFECTION;

EID: 84940890699     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2015.02.002     Document Type: Article

References (64)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Maggioni D., Biffi L., Nicolini G., Garavello W. Flavonoids in oral cancer prevention and therapy. Eur. J. Cancer Prev. 2014, 10.1097/CEJ.0000000000000109.
3. Elwood J.M., Pearson J.C., Skippen D.H., Jackson S.M. Alcohol, smoking, social and occupational factors in the aetiology of cancer of the oral cavity, pharynx and larynx. Int. J. Cancer 1984, 34:603-612.
4. Bonnet E., Wuyts J., Rouze P., Van de Peer Y. Evidence that microRNA precursors, unlike other non-coding RNAs, have lower folding free energies than random sequences. Bioinformatics 2004, 20:2911-2917.
5. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20:515-524.
6. Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., Lim B., Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
7. Chitwood D.H., Timmermans M.C. Small RNAs are on the move. Nature 2010, 467:415-419.
8. Tan G.S., Garchow B.G., Liu X., Metzler D., Kiriakidou M. Clarifying mammalian RISC assembly in vitro. BMC Mol. Biol. 2011, 12:19.
9. Hebert S.S., Sergeant N., Buee L. MicroRNAs and the regulation of tau metabolism. Int. J. Alzheimers Dis. 2012, 2012:406561.
10. Ui-Tei K., Nishi K., Takahashi T., Nagasawa T. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012, 3:101.
11. Yang J.S., Maurin T., Lai E.C. Functional parameters of Dicer-independent microRNA biogenesis. RNA 2012, 18:945-957.
12. Wang J., Li L.C. Small RNA and its application in andrology and urology. Transl. Androl. Urol. 2012, 1:33-43.
13. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
14. Saini S., Majid S., Yamamura S., Tabatabai L., Suh S.O., Shahryari V., Chen Y., Deng G., Tanaka Y., Dahiya R. Regulatory role of mir-203 in prostate Cancer progression and metastasis. Clin. Cancer Res. 2011, 17:5287-5298.
15. Wang C., Wang X., Liang H., Wang T., Yan X., Cao M., Wang N., Zhang S., Zen K., Zhang C., Chen X. miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCalpha. PLoS One 2013, 8:e73985.
16. Jin J., Deng J., Wang F., Xia X., Qiu T., Lu W., Li X., Zhang H., Gu X., Liu Y., Cao W., Shao W. The expression and function of microRNA-203 in lung cancer. Tumour Biol. 2013, 34:349-357.
17. Bueno M.J., Perez de Castro I., Gomez de Cedron M., Santos J., Calin G.A., Cigudosa J.C., Croce C.M., Fernandez-Piqueras J., Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496-506.
18. Kefalas P., Brown T.R., Brickell P.M. Signalling by the p60c-src family of protein-tyrosine kinases. Int. J. Biochem. Cell Biol. 1995, 27:551-563.
19. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13:513-609.
20. Kopetz S., Shah A.N., Gallick G.E. Src continues aging: current and future clinical directions. Clin. Cancer Res. 2007, 13:7232-7236.
21. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
22. Chan C.M., Jing X., Pike L.A., Zhou Q., Lim D.J., Sams S.B., Lund G.S., Sharma V., Haugen B.R., Schweppe R.E. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin. Cancer Res. 2012, 18:3580-3591.
23. Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin. Investig. Drugs 2010, 19:605-614.
24. Pena S.V., Melhem M.F., Meisler A.I., Cartwright C.A. Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 1995, 108:117-124.
25. Summy J.M., Sudol M., Eck M.J., Monteiro A.N., Gatesman A., Flynn D.C. Specificity in signaling by c-Yes. Front Biosci. 2003, 8:s185-205.
26. Clump D.A., Qazi I.H., Sudol M., Flynn D.C. c-Yes response to growth factor activation. Growth Factors 2005, 23:263-272.
27. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602:114-130.
28. Han N.M., Curley S.A., Gallick G.E. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin. Cancer Res. 1996, 2:1397-1404.
29. Choi H.K., Kim D.H., Kim J.W., Ngadiran S., Sarmidi M.R., Park C.S. Labisia pumila extract protects skin cells from photoaging caused by UVB irradiation. J. Biosci. Bioeng. 2010, 109:291-296.
30. Park C., Lee I., Kang W.K. Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis. Mol. Cancer Ther. 2006, 5:3191-3196.
31. Croteau W., Davey J.C., Galton V.A., St Germain D.L. Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J. Clin. Invest. 1996, 98:405-417.
32. Curcio C., Baqui M.M., Salvatore D., Rihn B.H., Mohr S., Harney J.W., Larsen P.R., Bianco A.C. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J. Biol. Chem. 2001, 276:30183-30187.
33. Arnaldi L.A., Borra R.C., Maciel R.M., Cerutti J.M. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 2005, 15:210-221.
34. Sepp M., Pruunsild P., Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum. Mol. Genet. 2012, 21:2873-2888.
35. Gheidari F., Bakhshandeh B., Teimoori-Toolabi L., Mehrtash A., Ghadir M., Zeinali S. TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug. Anticancer Drugs 2014, 25:908-916.
36. Waldmann T.A. Interleukin-15 in the treatment of cancer. Expert Rev. Clin. Immunol. 2014, 10:1689-1701.
37. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
38. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
39. Chim C.S., Wong K.Y., Qi Y., Loong F., Lam W.L., Wong L.G., Jin D.Y., Costello J.F., Liang R. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31:745-750.
40. Kano M., Seki N., Kikkawa N., Fujimura L., Hoshino I., Akutsu Y., Chiyomaru T., Enokida H., Nakagawa M., Matsubara H. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer 2010, 127:2804-2814.
41. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68:2094-2105.
42. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
43. Mathe E.A., Nguyen G.H., Bowman E.D., Zhao Y., Budhu A., Schetter A.J., Braun R., Reimers M., Kumamoto K., Hughes D., other 10 authors MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin. Cancer Res. 2009, 15:6192-6200.
44. Xie L., Zhang Z., Tan Z., He R., Zeng X., Xie Y., Li S., Tang G., Tang H., He X. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol. Cell. Biochem. 2014, 392:153-159.
45. Shen P.F., Chen X.Q., Liao Y.C., Chen N., Zhou Q., Wei Q., Li X., Wang J., Zeng H. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate 2014, 74:756-767.
46. Li B., Sun M., Gao F., Liu W., Yang Y., Liu H., Cheng Y., Liu C., Cai J. Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma. Cell Physiol. Biochem. 2013, 32:1729-1740.
47. Kim J.S., Yu S.K., Lee M.H., Park M.G., Park E., Kim S.G., Lee S.Y., Kim C.S., Kim H.J., Chun H.S., Chun S.W., Kim do K. MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Mol. Cells 2013, 35:17-24.
48. Tian L., Li M., Ge J., Guo Y., Sun Y., Liu M., Xiao H. MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 2014, 35:5953-5963.
49. Yuan Y., Zeng Z.Y., Liu X.H., Gong D.J., Tao J., Cheng H.Z., Huang S.D. MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 2011, 11:57.
50. Bo J., Yang G., Huo K., Jiang H., Zhang L., Liu D., Huang Y. microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J. 2011, 278:786-792.
51. Hemida M.G., Ye X., Zhang H.M., Hanson P.J., Liu Z., McManus B.M., Yang D. MicroRNA-203 enhances coxsackievirus B3 replication through targeting zinc finger protein-148. Cell Mol. Life Sci. 2013, 70:277-291.
52. Nahvi A., Shoemaker C.J., Green R. An expanded seed sequence definition accounts for full regulation of the hid 3' UTR by bantam miRNA. RNA 2009, 15:814-822.
53. Oikawa T., Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003, 303:11-34.
54. Seth A., Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005, 41:2462-2478.
55. Brenne K., Nymoen D.A., Hetland T.E., Trope C.G., Davidson B. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum. Pathol. 2012, 43:496-505.
56. Gereben B., Bartha T., Tu H.M., Harney J.W., Rudas P., Larsen P.R. Cloning and expression of the chicken type 2 iodothyronine 5'-deiodinase. J. Biol. Chem. 1999, 274:13768-13776.
57. Schmutzler C., Hoang-Vu C., Ruger B., Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur. J. Endocrinol. 2004, 150:547-556.
58. Schreck R., Schnieders F., Schmutzler C., Kohrle J. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 1994, 79:791-798.
59. Barraclough J., Hodgkinson C., Hogg A., Dive C., Welman A. Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia 2007, 9:745-754.
60. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., Thiemann M., Mueller W., Sykora J., Kuhn A., other 13 authors Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
61. Gregersen L.H., Jacobsen A.B., Frankel L.B., Wen J., Krogh A., Lund A.H. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010, 5:e8836.
62. Hao Q., Lu X., Liu N., Xue X., Li M., Zhang C., Qin X., Li W., Shu Z., Song B., other 4 authors Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development. BMB Rep. 2013, 46:316-321.
63. Majid S., Saini S., Dar A.A., Hirata H., Shahryari V., Tanaka Y., Yamamura S., Ueno K., Zaman M.S., Singh K., other 4 authors MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res. 2011, 71:2611-2621.
64. Fujita S., Iba H. Putative promoter regions of miRNA genes involved in evolutionarily conserved regulatory systems among vertebrates. Bioinformatics 2008, 24:303-308.